Topics

Agilvax, Inc. Company Profile

07:56 EDT 21st September 2019 | BioPortfolio

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critical role in the high rates of recurrence and poor outcomes in TNBC as compared with other forms of breast cancer. The company’s pipeline and drug discovery platform are based on VLPs derived from RNA bacteriophage that have been engineered to display antigens in an ordered geometric pattern, which can be utilized to stimulate robust and specific immune responses to both foreign pathogens and self-antigens. The Company was founded in 2011 and has headquarters in Albuquerque, New Mexico, and offices in El Paso, Texas.


News Articles [3 Associated News Articles listed on BioPortfolio]

AgilVax Triggers $2 Million Phase II Fast Track SBIR Grant and Initiates GMP Manufacturing

AgilVax, Inc., a biotechnology company developing targeted antibody-based therapies for the treatment of various cancers, including metastatic breast cancer (MBC), announce...

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

AgilVax Appoints Dr. Joseph Patti as Chief Executive Officer

AgilVax Inc., a biopharmaceutical company developing targeted antibody-based products to treat multiple types of cancer in combination with chemotherapy, checkpoint, and KRAS inhibitors, announced to...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Agilvax

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product,...

Agilvax, Inc.

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, ...

AgilVax Inc.

AgilVax is a biopharmaceutical company developing xCT antibody-based products to treat multiple types of cancer in combination with chemotherapy, checkpoint and KRAS inhibitors. The Company has two p...

More Information about "Agilvax, Inc." on BioPortfolio

We have published hundreds of Agilvax, Inc. news stories on BioPortfolio along with dozens of Agilvax, Inc. Clinical Trials and PubMed Articles about Agilvax, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Agilvax, Inc. Companies in our database. You can also find out about relevant Agilvax, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Corporate Database Quicklinks



Searches Linking to this Company Record